Renal cell carcinoma (RCC) shows variable FDG uptake; recently, PET/CT with prostate-specific membrane antigen (PSMA)-target radiotracers was demonstrated to be a promising tool in staging and restaging of RCC patients. We describe the case of a 77-year-old man with a lung metastasis of papillary RCC missed by CT scan who successfully underwent [18F]FDG PET/CT restaging. Targeted therapy with sunitinib was administered. A [68Ga]PSMA PET/CT performed during follow-up demonstrated, among the already known lesions, also a bone marrow metastasis, missed by previous CT scans. This case demonstrates that PET/CT molecular imaging with [18F]FDG and [68Ga]PSMA is superior to conventional imaging in RCC restaging and in assessing therapy response.
18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence / Gasparro, D.; Scarlattei, M.; Manuguerra, R.; Guglielmo, P.; Migliari, S.; Sammartano, A.; Baldari, G.; Maestroni, U.; Silini, E. M.; Ruffini, L.. - In: CLINICAL NUCLEAR MEDICINE. - ISSN 0363-9762. - 46:9(2021), pp. E458-E460. [10.1097/RLU.0000000000003660]
|Appare nelle tipologie:||1.1 Articolo su rivista|